Format

Send to

Choose Destination
Leuk Lymphoma. 2017 May;58(5):1022-1036. doi: 10.1080/10428194.2016.1228927. Epub 2016 Sep 21.

Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.

Author information

1
a Department of Medicine (Hematology) , Yale School of Medicine , New Haven , CT , USA.

Abstract

The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a significant advancement, HMA lead to responses in less than half of patients and for those that respond most will relapse. As such, there is a crucial need to improve frontline therapy approaches. One promising strategy involves combining azacitidine or decitabine with investigational or existing therapies with the goal of achieving synergistic activity and better patient outcomes. The purpose of this paper is to critically review the efficacy and safety of reported HMA-based combination regimens in patients with higher-risk MDS.

KEYWORDS:

AML; DNA methyltransferase inhibitor; MDS; combination therapy; epigenetic; hypomethylating agent

PMID:
27654579
PMCID:
PMC5785935
DOI:
10.1080/10428194.2016.1228927
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center